Jasper Therapeutics, Inc. 8-K

What Happened
Jasper Therapeutics, Inc. announced on July 16, 2026 (via a Form 8‑K Regulation FD disclosure) that it has completed the acquisition of Kira Pharmaceuticals, a former Cayman limited company focused on designing complement therapies to treat immune‑mediated diseases, in an all‑stock transaction. On the same date the company entered into a securities purchase agreement for a private placement financing with gross proceeds of $132 million. A press release describing these developments was furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Acquisition completed: Kira Pharmaceuticals acquired by Jasper in an all‑stock transaction (closing date July 16, 2026).
• Business focus of target: Kira designed complement therapies for immune‑mediated diseases.
• Financing: Securities purchase agreement for private placement providing gross proceeds of $132 million.
• Disclosure: Information announced under Regulation FD and filed on Form 8‑K; press release included as Exhibit 99.1.

Why It Matters
These actions expand Jasper’s pipeline into complement‑directed therapies and add assets and personnel from Kira. The all‑stock nature of the deal means consideration was paid in Jasper shares rather than cash, which impacts share count and ownership structure. The $132 million private placement provides a substantial capital infusion that can be used to fund development, operations, or integration activities. Retail investors should watch future filings for details on share issuance, use of proceeds, and any updates to clinical or corporate plans.